HOUSTON--(BUSINESS WIRE)--Idera, Inc., parent company of global B2B software productivity brands, today announced the acquisition of Kiuwan, a SaaS solution for measuring and analyzing risk and ...

HOUSTON, TX--(Marketwired - Jun 18, 2013) - Idera, a leading provider of application and server management solutions, today announced that VCE, a leading converged cloud infrastructure systems ...

LAS VEGAS, NV--(Marketwired - May 16, 2013) - In booth 17 at the Lifeboat Partner Summit West, Idera, a leading provider of application and server management solutions, announced that the Company ...

Idera, a provider of management and administration solutions for Microsoft Windows Servers, has announced the latest version of SQL diagnostic manager, 6.0. The tool is a SQL Server performance and ...

IDERA, a provider of database lifecycle management solutions, is extending its product portfolio by adding Embarcadero Technologies’ ER/Studio and DB PowerStudio tools, allowing organizations to rely ...

New AI capabilities help DBAs move from performance visibility to performance resolution—turning slow queries into actionable index recommendations in minutes HOUSTON, March 19, 2026 /PRNewswire/ -- ...

Partners Group has taken a controlling stake in Idera in a transaction that values the business-to-business software company at close to $3 billion, sources familiar with the deal’s terms told PE Hub.

HOUSTON—May 23, 2019—Idera, Inc. (“Idera” or “the Company”), parent company of global B2B software productivity brands, today announced it will receive a new minority investment from Partners Group, a ...

HOUSTON, May 23, 2019 /PRNewswire/ -- Idera, Inc. ("Idera" or "the Company"), parent company of global B2B software productivity brands, today announced it will receive a new minority investment from ...

Shares of Idera Pharmaceuticals (NASDAQ: IDRA) are down around 15% year to date. And that's a good thing, relatively speaking: The clinical-stage biotech's stock was down by more than 55% just a few ...

Cambridge, Mass.-based Idera Pharmaceuticals and Bermuda-based Vivelix Pharmaceuticals entered into an exclusive license and collaboration agreement giving Vivelix the rights to develop and market IMO ...